Page last updated: 2024-09-03

troxacitabine and Benign Neoplasms

troxacitabine has been researched along with Benign Neoplasms in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (90.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW1
Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH1
Ecker, G1
Gourdeau, H; Jolivet, J1
Boudreau, C; Custeau, D; Dong, K; Gilbert, MJ; Gourdeau, H; Hamelin, B; Jolivet, J; Leblond, L; Ouellet, F; Richard, A1
Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK1
Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Lee, CK; Ma, WW; Messersmith, WA1
Baker, SD; de Bono, JS; Goetz, A; Hammond, LA; Hidalgo, M; Jolivet, J; Patnaik, A; Rowinsky, EK; Simmons, C; Siu, L; Stephenson, J; Weiss, G1
Baker, SD; Bélanger, K; Dionne, J; Jolivet, J; Maclean, M; Moore, M; Seymour, L; Siu, L; Soulières, D; Wainman, N1

Reviews

1 review(s) available for troxacitabine and Benign Neoplasms

ArticleYear
[Troxacitabine].
    Bulletin du cancer, 2004, Volume: 91, Issue:3

    Topics: Acute Disease; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytosine; Dioxolanes; Drug Screening Assays, Antitumor; Humans; Leukemia; Neoplasms

2004

Trials

5 trial(s) available for troxacitabine and Benign Neoplasms

ArticleYear
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Tissue Distribution; Treatment Outcome; Young Adult

2009
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1

    Topics: Antineoplastic Agents; Body Fluid Compartments; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Middle Aged; Models, Biological; Molecular Structure; Neoplasms; Predictive Value of Tests; Structure-Activity Relationship

2006
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2

    Topics: Adult; Aged; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Predictive Value of Tests; Probability; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome

2008
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-01, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Eruptions; Female; Half-Life; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Regression Analysis; Salvage Therapy; Statistics, Nonparametric; Stereoisomerism; Structure-Activity Relationship

2002
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, May-15, Volume: 20, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Dioxolanes; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Thrombocytopenia; Tissue Distribution

2002

Other Studies

4 other study(ies) available for troxacitabine and Benign Neoplasms

ArticleYear
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Female; Humans; Male; Middle Aged; Models, Biological; Monte Carlo Method; Neoplasms; Neutropenia; Young Adult

2011
Troxacitabine (Shire Pharmaceuticals).
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:10

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Humans; Neoplasms; Structure-Activity Relationship

2002
Troxacitabine: BCH 4556, SPD 758, Troxatyl.
    Drugs in R&D, 2003, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Drug Industry; Humans; Infusions, Intravenous; Neoplasms; Treatment Outcome

2003
Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Male; Mice; Neoplasm Transplantation; Neoplasms; Species Specificity; Time Factors

2004